New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
FDA approves new drug to treat Alzheimer’s
Jul 02, 2024
In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
FDA OKs marketing of new test to help diagnose Alzheimer disease
May 06, 2022
The test is indicated for patients 55 years and older who present with cognitive impairment and are being evaluated for Alzheimer’s disease and cognitive decline.
Nearly 7 million Americans have Alzheimer’s, and caregivers are stressed
Mar 20, 2024
Nearly 7 million American seniors are living with Alzheimer’s dementia, placing a huge strain on both personal caregivers and the US healthcare system, according to a new Alzheimer’s Association...
Higher, lower HDL cholesterol linked to increased risk for dementia
Oct 04, 2023
An increased risk for Alzheimer’s disease and related dementia was seen in association with higher and lower versus middle quintile of HDL-C.
Two major health systems will not administer controversial Aduhelm
Jul 15, 2021
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion.
Inverse link found for antioxidant levels, all-cause dementia
May 04, 2022
Serum lutein+zeaxanthin and β-cryptoxanthin levels were inversely associated with incident all-cause dementia.
Eligibility limited for anti-β amyloid mAbs in seniors with MCI
Aug 18, 2023
Few older adults with mild cognitive impairment or mild dementia were eligible for lecanemab or aducanumab after applying clinical trial criteria.
Higher education may protect functioning with Alzheimer’s disease
Apr 03, 2024
The findings were seen among African American individuals, with greater protective effect in APOE ɛ4 noncarriers.